Disclaimer. This site reads publicly available research papers and corporate filings and explains what they say. It is not investment advice and does not recommend buying or selling any security. Historical cases shown here are computed from public data; the sample sizes are small and are not a basis for prediction. We do not answer questions about individual stocks.
Readouts · Company page
Novo Nordisk
Company facts
- Status
- NYSE NVO
- Headquarters
- BAGSVAERD DENMARK, G7
- Industry
- Pharmaceutical Preparations SIC 2834
- Fiscal year end
- 1231
- Links
- Quote · TradingView
- Source
- SEC
Financial summary (from filings)
| 2023 | 2024 | 2025 | |
|---|---|---|---|
| Revenue | 232,261 | 290,403 | 309,064 |
| Operating income | 102,574 | 128,339 | 127,658 |
| Net income | 83,683 | 100,988 | 102,434 |
| Total assets | 314,486 | 465,630 | 542,902 |
| Total liabilities | 207,925 | 322,144 | 348,855 |
| Total equity | 106,561 | 143,486 | 194,047 |
Unit: USD million · Consolidated statements · Source SEC 10-K/20-F
Figures are copied from the filing with only the unit changed. No growth rates or assessments are shown.
Readouts that mention this company
National R&D projects (NTIS)
7
item
1,211,000,000
Cumulative government R&D funding (KRW)
Largest projects
- 폐암 환자의 혈액 내 cfDNA 대상 차세대염기서열분석 기반 다 유전자변이 검출키트 및 소프트웨어 개발 2017 · 중소벤처기업부
- 이오나이저 빅데이터 관리 시스템 개발 2026 · 중소벤처기업부
- 폐암 환자의 혈액 내 cfDNA 대상 차세대염기서열분석 기반 다 유전자변이 검출키트 및 소프트웨어 개발 2016 · 중소기업청
Korean patent filings (KIPRIS)
국내 출원인 표기 없음
Papers with affiliated authors (OpenAlex)
686
item
Papers by year
| 2025 |
|---|
| 686 |
Companies in the same readouts
- Dong-A ST
- Chugai Pharmaceutical
- Eli Lilly
- Hangzhou Zhongmei Huadong
- Jiangsu Hengrui
- Eccogene
- Hanmi Pharmaceutical
- LG H&H
Last updated 2026-09-21